Pharmaceuticals

Rising Prevalence Of Pancreatic Cancer Fueling The Growth Of The Market Due To Increasing Demand For Personalized And Targeted Therapies Is Supporting Development Across The Pancreatic Cancer Precision Medicine Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Pancreatic Cancer Precision Medicine Market Progress Through 2030?

The market size for pancreatic cancer precision medicine has seen rapid expansion in recent years. It is anticipated to grow from $0.58 billion in 2025 to $0.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.7%. This growth historically stems from factors such as poor survival rates associated with conventional therapies, progress in cancer genomics, an increasing incidence of pancreatic cancer, expanded funding for oncology research, and the early successes of targeted therapies.

The pancreatic cancer precision medicine market size is projected to experience considerable growth in the coming years. It will grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. This expansion during the forecast period can be attributed to increased adoption of precision oncology, rising investment in pancreatic cancer research, advancements in diagnostic technologies, the broadening of immunotherapy pipelines, and the growing application of companion diagnostics. Significant trends for the forecast period include the increasing use of genomic and molecular profiling, the wider adoption of biomarker-based therapies, the expansion of targeted and immunotherapy combinations, the rising use of liquid biopsy diagnostics, and a greater emphasis on personalized treatment pathways.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24354&type=smp

What Core Drivers Are Transforming The Pancreatic Cancer Precision Medicine Market?

An anticipated increase in the incidence of pancreatic cancer is projected to fuel the expansion of the pancreatic cancer precision medicine market in the coming period. This form of cancer originates in the cells of the pancreas, an organ vital for both digestive processes and maintaining stable blood sugar levels. The escalating occurrence of pancreatic cancer is attributed to an aging global demographic alongside an increasing incidence of associated risk factors like obesity, diabetes, and smoking. Pancreatic cancer precision medicine improves how cancer is managed by providing customized treatment strategies that are informed by an individual’s genetic and molecular profiles. Such medicine boosts the efficacy of treatments and minimizes adverse reactions, thus establishing itself as an indispensable method for more effective pancreatic cancer management. As an illustration, Cancer Australia, a government organization based in Australia, reported in February 2025 that 4,641 new cases of pancreatic cancer were recorded in 2024, comprising 2,414 males and 2,227 females, which signifies a rise from 3,968 cases observed in 2023. Consequently, the increasing occurrence of pancreatic cancer is serving as a catalyst for the expansion of the pancreatic cancer precision medicine market.

What Segment Categories Are Evaluated In The Pancreatic Cancer Precision Medicine Market Study?

The pancreatic cancer precision medicine market covered in this report is segmented –

1) By Therapeutic Approach: Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approaches

2) By Diagnostic Technology: Genomic Testing, Molecular Diagnostics, Liquid Biopsy, Biomarker-Based Companion Diagnostics, Other Diagnostic Technologies

3) By Application: Hospitals, Specialty Clinics, Academic And Research Institutes, Diagnostic Centers

Subsegments:

1) By Targeted Therapy: Kinase Inhibitors, PARP Inhibitors

2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy

3) By Chemotherapy-Precision Combinations: Gemcitabine-Based Combinations, Fluorouracil-Based Combinations, Nab-Paclitaxel-Based Combinations

4) By Other Therapeutic Approaches: RNA-Based Therapies, Epigenetic Modulators, Antibody-Drug Conjugates (ADCs)

What Trends Are Influencing The Pancreatic Cancer Precision Medicine Market?

Major companies operating in the pancreatic cancer precision medicine market are focusing on developing advanced technologies, such as precision medical tool, to enhance early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for improved patient outcomes. A precision medical tool is a specialized device that helps diagnose and treat diseases accurately based on a person’s unique biology. For instance, in January 2024, Cedars-Sinai, a US-based hospital and healthcare company, launched molecular twin precision oncology platform, a precision medical tool to better predict pancreatic cancer survival by identifying key biomarkers. The platform’s strong potential lies in guiding treatment decisions, even in areas with limited resources, by using blood and tissue samples from 74 patients with pancreatic ductal adenocarcinoma to offer a more accurate and accessible approach to precision oncology.

Which Organizations Are Operating Within The Pancreatic Cancer Precision Medicine Market?

Major companies operating in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Amgen Inc., Eli Lilly and Company, Genentech Inc., Ipsen Pharma, Bayer AG, Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health, Foundation Medicine Inc., Oncolytics Biotech Inc., Erytech Pharma, PharmaCyte Biotech Inc., Celgene Corporation, Natera Inc.

Access The Complete Pancreatic Cancer Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-precision-medicine-global-market-report

Which Region Holds The Largest Share In The Pancreatic Cancer Precision Medicine Market?

North America was the largest region in the pancreatic cancer precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pancreatic Cancer Precision Medicine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24354&type=smp

Browse Through More Reports Similar to the Global Pancreatic Cancer Precision Medicine Market 2026, By The Business Research Company

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Pancreatic Cancer Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795